Responsive Menu
Add more content here...

Uncensored News – Tru News

BOMBSHELL: Remdesivir U.S. Fauci Protocol: An Epidemic Failure and Patient Death


SPR and other independent experts warned early on that the very expensive “anti-viral” drug remdesivir, produced by Gilead and promoted by the media, is a failure. Dr. Paul Marik, author of the EVMS Covid-19 Critical Care Protocol, called remdesivir a “particularly useless drug” and Gilead’s aggressive marketing campaign “Wall Street centered, not patient-centered”.

The newly published results of the global WHO Solidarity trial now confirm that remdesivir reduces neither hospital stay (time to recovery) nor mortality. But remdesivir is not just a “useless drug”, it may in fact be a dangerous one, as its liver and kidney toxicity in covid patients has been widely documented and is currently being investigated by the European Medicines Agency (EMA).

Investigative journalist Dilyana Gaytandzhieva recently revealed how Gilead paid more than $200 million to US doctors and hospitals to promote its drugs despite several hundred drug-related deaths (this is referring to Gilead’s hepatitis C drug, in particular).

Moreover, several of the fraudulent anti-HCQ studies were published by researchers linked to or paid by remdesivir producer Gilead. The WHO trial itself used toxic overdoses of HCQ, as first revealed by US doctor and biohazard expert Meryl Nass in June (the WHO trial was halted thereafter).

(Update: As the Guardian reports, Gilead knew about the negative WHO trial results since September 23, but nevertheless signed a $1 billion deal for 500,000 doses of remdesivir with the European Commission, which did not yet know about the results, on October 8.)

Based on current scientific and clinical evidence, it is best to treat high-risk covid patients as early as possible to avoid disease progression and hospitalization. For more information, see the recent video presentation on ambulatory treatment of covid by Dr. Peter McCullough.

More SourcesWorld’s top intensive care body advises against remdesivir (Reuters)